A Study of EXG102-031 in Participants With wAMD
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Biological: EXG102-031
- Registration Number
- NCT06183814
- Lead Sponsor
- Hangzhou Jiayin Biotech Ltd
- Brief Summary
In neovascular (wet) age-related macular degeneration (wAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with wAMD.
- Detailed Description
Age-related macular degeneration (AMD) is a major cause of blindness and visual impairment in older adults. The wet form of AMD, also called neovascular AMD (nAMD) usually causes faster vision loss than the dry form. The most common current treatments of nAMD are products that inhibit vascular endothelial growth factor (VEGF) (including ranibizumab (LUCENTIS®, Genentech) and aflibercept (EYLEA®, Regeneron) and are delivered by intravitreal injections at 4 to 16 week intervals and continued indefinitely. This Open-label, Dose-escalation Phase I/IIa Study is designed to evaluate the safety and efficacy of EXG102-031 intraocular Injection in participants with wet(Neovascular) Age-related Macular Degeneration（wAMD）.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 42
- Male or female, age ≥ 50 years of age;
- Diagnosis of wAMD and current active lesion in the study eye at Screening;
- An ETDRS BCVA letter scores between 73 and 9 letters in the study eye;
- Response to anti-VEGF treatment within 6 months prior to screening or at the time of screening introduction;
- The study eye must be a Intraocular lens eye(post-cataract surgery status) and be at least 1 month post IOL implantation at enrollment;
- Voluntarily agree to participate in the clinical trial, understand the trial procedures, and be capable of signing the informed consent form before screening.
- Presence of any ocular disease or history of disease in the study eye other than wAMD that may affect central visual acuity and/or macular detection;
- Presence in the study eye of CNV or macular pathology pathography due to causes other than wAMD;
- The study eye has severe and irreversible retinal structural damage involving the fovea (such as retinal pigment epithelial (RPE) atrophy, retinal fibrosis, laser scars, dense hard exudation); Or other retinal damage in the target eye that, in the opinion of the investigator, may impede visual improvement after resolution of macular edema ;
- Subretinal hemorrhage accumulating the central fovea of the study eye, with an area of hemorrhage ≥ 4 optic disc diameters;
- Presence of advanced glaucoma or uncontrolled ocular hypertension in the study eye;
- Prior receipt of any ocular or systemic gene therapy agent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Dose escalation-Cohort 3 EXG102-031 Genetic : EXG102-031 Dose escalation-Cohort 4 EXG102-031 Genetic : EXG102-031 Dose escalation-Cohort 5 EXG102-031 Genetic : EXG102-031 Dose escalation-Cohort 1 EXG102-031 Genetic : EXG102-031 Dose escalation-Cohort 2 EXG102-031 Genetic : EXG102-031
- Primary Outcome Measures
Name Time Method Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events) 24 weeks following EXG102-031 administration incidence of ocular and non-ocular AEs and SAEs
- Secondary Outcome Measures
Name Time Method Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events) 52 weeks following EXG102-031 administration incidence of ocular and non-ocular AEs and SAEs
Change From Baseline in BCVA (Best Corrected Visual Acuity) 52 weeks following EXG102-031 administration Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision.
Change From Baseline in CRT (Central Retinal Thickness) 52 weeks following EXG102-031 administration Retinal fluid status of the study eye was evaluated using spectral domain OCT (Optical Coherence Tomography). A decrease in value indicates a decrease in fluid
Supplemental Injections (Annualized Rate of Supplemental Injections) 52 weeks following EXG102-031 administration The number of supplemental anti-VEGF injections given after EXG102-031 was administered.
Trial Locations
- Locations (8)
Jiangsu Provinve Hospital
🇨🇳Nanjing, Jiangsu, China
Beijing Tongren Hospital,Cmu
🇨🇳Peking, Beijing, China
Eye Hospital,WMU
🇨🇳Wenzhou, Zhejiang, China
The Second Affiliated Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
Beijing Hospital
🇨🇳Peking, Beijing, China
Peking University People'S Hospital
🇨🇳Peking, Beijing, China
The Southwest Hospital of Amu
🇨🇳Chongqing, Chongqing, China
Central theater General Hospital
🇨🇳Wuhai, Hubei, China